Clearside Biomedical And 3 Other Stocks Under $3 Insiders Are Buying

The Dow Jones closed higher by over 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Glatfelter

• The Trade: Glatfelter Corporation GLT 10% owner Duane Clint Carlson acquired a total of 325,000 shares an average price of $1.94. To acquire these shares, it cost around $630,925.
• What’s Happening: Glatfelter entered into an agreement with Ekman & Co. to market Glatfelter's high quality, specialty Abaca pulp exclusively through Ekman's global sales agency platform.
• What Glatfelter Does: Glatfelter Corporation manufactures and sells a variety of paper and fiber products. The company operates through two segments: Composite Fibers and Airlaid Materials.

NetSol Technologies

• The Trade: NetSol Technologies, Inc. NTWK CEO Najeeb Ghauri acquired a total of 5,000 shares at an average price of $1.90. To acquire these shares, it cost around $9,500.
• What’s Happening: NETSOL Technologies reported a year-over-year decrease in fourth-quarter EPS results and issued FY24 revenue guidance.
• What NetSol Technologies Does: NETSOL Technologies Inc is involved in providing information technology and enterprise software solutions.

Check This Out: MaxCyte, Rivian Automotive And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Clearside Biomedical

• The Trade: Clearside Biomedical, Inc. CLSD Director Nancy Hutson acquired a total of 10,000 shares at an average price of $0.86. The insider spent $8,600 to buy those shares.
• What’s Happening: Clearside Biomedical posted a wider-than-expected second-quarter loss.
• What Clearside Biomedical Does: Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS.

Lixte Biotechnology

• The Trade: Lixte Biotechnology Holdings, Inc. LIXT Director Rene Bernards acquired a total of 10,000 shares at an average price of $2.41. The insider spent around $24,116.
• What’s Happening: LIXTE recently named Bas Van Der Baan as President and Chief Executive Officer.
• What Lixte Biotechnology Does: Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound.

Don’t forget to check out our premarket coverage here